When people think of plasma donation centers the first things that come to mind are needles had helping others. Besides plasma donations being vital for people with organ transplants and hemophilia, ...

Feb. 27—Two Southern Oregon residents are suing CSL Plasma for millions of dollars, saying that their blood plasma donations in Medford caused them stints in the hospital lasting months and ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

Plasma, gathered mainly from paid donations in the US, is the raw ingredient needed to produce CSL’s suite of lifesaving products, including its immunoglobulins, conventional haemophilia treatment and ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

Australia’s largest listed company, CSL, has defended its position as an ethical provider of needed blood plasma that is made into life saving medicines, after a report raised concerns around the ...

Add articles to your saved list and come back to them any time. CSL boss Paul McKenzie is looking to make the company’s multi-billion dollar blood plasma business more efficient as the biotech tackles ...

CSL Ltd., an Australian maker of blood-plasma therapeutics, says it is exploring whether it can develop a plasma product to treat Ebola. Chief Executive Paul Perreault said he formed a small team to ...

Add articles to your saved list and come back to them any time. Stocks watchers are focusing on the value CSL can extract from its blockbuster acquisition of Swiss pharma firm Vifor as turbulence in ...